Drug Combination Details
| General Information of the Combination (ID: C76871) | |||||
|---|---|---|---|---|---|
| Name | Flavopiridol NP Info | + | Irinotecan Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | RAD51 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G2 phase | ||||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| In-vivo Model | Athymic-NCr-nu male mice (8-10 weeks of age) were inoculated subcutaneously in the flank with minced p21-intact HCT116 cells mixed with Matrigel. | |||||
| Experimental
Result(s) |
CPT-11 induces cell cycle arrest rather than cell death and that flavopiridol, by activating the caspase cascade, cleaves the inhibitors of apoptosis and sensitizes the cells to undergo cell death. | |||||
